Incretin Atlas › Trials › US Phase 2 (NCT06737042)
US Phase 2 (NCT06737042)
Bofanglutide (GZR18) · obesity
Design
- Molecule(s)
- Bofanglutide (GZR18)
- Population
- obesity
- Phase
- 2
- Participants
- 326
- Duration
- 36 weeks
- Registry
- NCT06737042
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48 mg Q2W vs tirzepatide 15 mg QW (open-label active comparator): weight -16.93 % | obesity | 36 | 326 | — | —−15.2 % estimand not specified | — | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (1)
- 48 mg Q2W · weight_unsp · press release
the 48 mg bofanglutide injection group achieved an average weight loss of 15.18%
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: US Phase 2 (NCT06737042). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/us-phase-2-nct06737042/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.